PT  - JOURNAL ARTICLE
AU  - Bruce Schultz
AU  - Andrea Zaliani
AU  - Christian Ebeling
AU  - Jeanette Reinshagen
AU  - Denisa Bojkova
AU  - Vanessa Lage-Rupprecht
AU  - Reagon Karki
AU  - Sören Lukassen
AU  - Yojana Gadiya
AU  - Neal G. Ravindra
AU  - Sayoni Das
AU  - Shounak Baksi
AU  - Daniel Domingo-Fernández
AU  - Manuel Lentzen
AU  - Mark Strivens
AU  - Tamara Raschka
AU  - Jindrich Cinatl
AU  - Lauren Nicole DeLong
AU  - Phil Gribbon
AU  - Gerd Geisslinger
AU  - Sandra Ciesek
AU  - David van Dijk
AU  - Steve Gardner
AU  - Alpha Tom Kodamullil
AU  - Holger Fröhlich
AU  - Manuel Peitsch
AU  - Marc Jacobs
AU  - Julia Hoeng
AU  - Roland Eils
AU  - Carsten Claussen
AU  - Martin Hofmann-Apitius
TI  - The COVID-19 PHARMACOME: Rational Selection of Drug Repurposing Candidates from Multimodal Knowledge Harmonization
AID  - 10.1101/2020.09.23.308239
DP  - 2020 Jan 01
TA  - bioRxiv
PG  - 2020.09.23.308239
4099  - http://biorxiv.org/content/early/2020/09/23/2020.09.23.308239.short
4100  - http://biorxiv.org/content/early/2020/09/23/2020.09.23.308239.full
AB  - The SARS-CoV-2 pandemic has challenged researchers at a global scale. The scientific community’s massive response has resulted in a flood of experiments, analyses, hypotheses, and publications, especially in the field drug repurposing. However, many of the proposed therapeutic compounds obtained from SARS-CoV-2 specific assays are not in agreement and thus demonstrate the need for a singular source of COVID-19 related information from which a rational selection of drug repurposing candidates can be made. In this paper, we present the COVID-19 PHARMACOME, a comprehensive drug-target-mechanism graph generated from a compilation of several disease maps and experimental data focused on SARS-CoV-2 / COVID-19 pathophysiology. By applying a systematic approach, we were able to predict the effect of drug pairs on SARS-CoV-2 infection. Experimental validation of our results demonstrate that our graph can be used to not only explore the involved mechanistic pathways, but also to identify novel combinations of drug repurposing candidates.Competing Interest StatementThe authors have declared no competing interest.